• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Management Challenges for FY 2011

 Back to Table of Contents: FY 2010 MDUFMA Financial Reports

 

On September 27, 2007, the President signed the Food and Drug Administration Amendments Act of 2007 (FDAAA). Title II of FDAAA, the Medical Device User Fee Amendments of 2007, reauthorizes medical device user fees for FY 2008 through FY 2012 (MDUFMA II). MDUFMA II calls for a new set of challenging performance goals and a new fee structure.
 
FDA will continue to monitor performance against the goals for the MDUFMA I cohorts that remain open (FY 2004 through FY 2007; the FY 2003 cohort is now closed) and against the new performance goals of MDUFMA II. 
 
The performance goals for applications filed or accepted from FY 2008 through FY 2012 are defined in a September 27, 2007, letter from former HHS Secretary Michael O. Leavitt to Congress; see the following table for a summary of these goals.
 

Medical Device Review Performance Goals for FY 2008 through FY 2012
Application Type
Type of Goal
Review Time Goal
Performance Goal
Premarket approval application (PMA), panel-track PMA supplement, premarket report
FDA Decision
180 days
60%
295 days
90%
Expedited PMA, expedited panel-track PMA supplement
FDA Decision
180 days
50%
280 days
90%
PMA module
FDA Action
90 days
75%
120 days
90%
180-day PMA supplement
FDA Decision
180 days
85%
210 days
95%
Real-time PMA supplement
FDA Decision
60 days
80%
90 days
90%
510(k) premarket notification
Substantially Equivalent (SE) or Not Substantially Equivalent (NSE) Decision
90 days
90%
150 days
98%

 

An "FDA Decision" is any of the following: an approvable letter (including approvable pending GMP inspection), a non-approvable letter, a withdrawal, or a denial order.
An “FDA Action” on a PMA module is any of the following: accepting the module, a request for additional information, receipt of the PMA, or withdrawal of the module.
These goals are structured in ways that differ from the goals for FY 2003 through FY 2007:
  • The FY 2008 – FY 2012 goals do not vary from one fiscal year to the next. Instead, each goal will apply throughout the five years from FY 2008 through FY 2012.
  • Except for PMA modules, all of FDA’s performance goals focus on making an “FDA decision” and FDA will not have any cycle goals.  PMA decisions are approval, approvable, approvable pending Good Manufacturing Practices (GMP) inspection, not approvable, withdrawal, and denial. 510(k) decisions are substantially equivalent (SE) or not substantially equivalent (NSE).
  • For PMA modules only, FDA’s performance goals focus on FDA taking an “action” on the module.  An “FDA action” on a PMA module is any of the following: accepting the module, a request for additional information, receipt of the PMA, or withdrawal of the module.  PMA modules are not subject to a decision goal, because the modular submission is converted to a PMA upon submission of the final module.
  • Each goal has two tiers, and all submissions are measured in both tiers.  Compared with the lower tier, the upper tier of each goal provides for additional review time, but requires a higher percentage of reviews to have an FDA decision (or, in the case of PMA modules, an FDA action) within the specified review time. The use of two tiers helps ensure that FDA focuses on all applications within a cohort, rather than just those that are most likely to reach an FDA decision quickly.

 

Next Section: Appendix A - Statutory Conditions for Collection and Use of Fees